The Tribunal reasonably concluded CarGurus failed to provide sufficient, non‑speculative and cogent evidence (including a credible basis for its projections and reliable market share data) to establish a reasonable possibility of being directly and substantially affected by Trader's conduct under ss.75 and 77 of the Competition Act; the Federal Court of Appeal dismissed the appeal and upheld the Tribunal's leave denial.
The Federal Court fixed the factual parameters for Teva’s damages claim in a pregabalin patent matter and remained seized to complete final calculations.